ArticleFrontiers in pharmacology2019
Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
11.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 132 citations in OpenAlex.
- Trial
- Benzbromarone as adjuvant therapy for cystic fibrosis lung disease: a pilot clinical trial.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Trial
- Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.JAMA network open · 2022Trial
- Advances in the Treatment of Autosomal Dominant Polycystic Kidney Disease and Novel Therapeutic Targets.Current issues in molecular biology · 2026Review
- Article
- Transforming Niclosamide through Nanotechnology: A Promising Approach for Long COVID Management.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- [Transmembrane protein 16A--a new target for the treatment of airway inflammatory diseases].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2025Review
- Channeling Relaxation through Multiple Means: TMEM16A Antagonism for Asthma.American journal of respiratory cell and molecular biology · 2025Article
- TMEM16A Antagonism: Therapeutic Potential with Desensitization of β-Agonist Responsiveness in Asthma.American journal of respiratory cell and molecular biology · 2025Article
- DTIAM: a unified framework for predicting drug-target interactions, binding affinities and drug mechanisms.Nature communications · 2025Article
- The emerging role of transmembrane proteins in tumorigenesis and therapy.Translational cancer research · 2025Review
- ANO1: central role and clinical significance in non-neoplastic and neoplastic diseases.Frontiers in immunology · 2025Review
- Distinct modulation of calcium-activated chloride channel TMEM16A by drug-binding sites.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The Tmem16a chloride channel is required for mucin maturation after secretion from goblet-like cells in the Xenopus tropicalis tadpole skin.Scientific reports · 2024Article
- TMEM16 proteins: CaInternational journal of molecular medicine · 2024Review
- Niclosamide potentiates TMEM16A and induces vasoconstriction.The Journal of general physiology · 2024Article
- Predicting lung exposure of intramuscular niclosamide as an antiviral agent: Power-law based pharmacokinetic modeling.Clinical and translational science · 2024Article
- Niclosamide, but not ivermectin, inhibits anoctamin 1 and 6 and attenuates inflammation of the respiratory tract.Pflugers Archiv : European journal of physiology · 2024Article
- Inhibition of mucus secretion by niclosamide and benzbromarone in airways and intestine.Scientific reports · 2024Article
- Protein nanoparticles induce the activation of voltage-dependent non-selective ion channels to modulate biological osmotic pressure in cytotoxic cerebral edema.Frontiers in pharmacology · 2024Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 3 institutions in 2 countries.
Kent MinerDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Katja LabitzkeDepartment of Therapeutic Discovery, Amgen Inc., Regensburg, Germany.
Benxian LiuDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Paul WangDepartment of Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA, United States.
Kathryn HenckelsDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Kevin GaidaDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Robin ElliottDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Jian Jeffrey ChenDepartment of Medicinal Chemistry, Amgen Inc., Thousand Oaks, CA, United States.
Longbin LiuDepartment of Medicinal Chemistry, Amgen Inc., Thousand Oaks, CA, United States.
Anh LeithDepartment of Inflammation Research, Amgen Inc., Seattle, WA, United States.
Esther TruebloodDepartment of Comparative Biology and Safety Sciences, Amgen Inc., Seattle, WA, United States.
Kelly HensleyDepartment of Comparative Biology and Safety Sciences, Amgen Inc., Seattle, WA, United States.
Xing-Zhong XiaDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Oliver HomannGenome Analysis Unit, Amgen Inc., South San Francisco, CA, United States.
Brian BennettDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Mike FiorinoDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
John WhoriskeyDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Gang YuDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Sabine EscobarDepartment of Inflammation Research, Amgen Inc., Seattle, WA, United States.
Min WongDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Teresa L BornDepartment of Inflammation Research, Amgen Inc., Seattle, WA, United States.
Alison BudelskyDepartment of Inflammation Research, Amgen Inc., Seattle, WA, United States.
Mike ComeauDepartment of Inflammation Research, Amgen Inc., Seattle, WA, United States.
Dirk SmithDepartment of Inflammation Research, Amgen Inc., Seattle, WA, United States.
Jonathan PhillipsDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
James A JohnstonDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Joseph G McGivernDepartment of Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA, United States.
Kerstin WeiklDepartment of Therapeutic Discovery, Amgen Inc., Regensburg, Germany.
David PowersDepartment of Therapeutic Discovery, Amgen Inc., Thousand Oaks, CA, United States.
Karl KunzelmannInstitut für Physiologie, Universität Regensburg, Regensburg, Germany.
Deanna MohnDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Andreas HochheimerDepartment of Therapeutic Discovery, Amgen Inc., Regensburg, Germany.
John K SullivanDepartment of Inflammation Research, Amgen Inc., Thousand Oaks, CA, United States.
Amgen (United States) · USAmgen (Germany) · DEUniversity of Regensburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is an unmet need in severe asthma where approximately 40% of patients exhibit poor β-agonist responsiveness, suffer daily symptoms and show frequent exacerbations. Antagonists of the Ca
Indexed as
airway smooth muscle (ASM)bronchodilatorcalcium-activated chloride channeldesensitizationdrug repositioningniclosamidenitazoxanideTMEM16A antagonist
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.